ReviewEuropean journal of pediatrics2026
Surfactant therapy in neonatal care: advances, challenges, and practical considerations.
Review in European journal of pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Surfactant therapy is a cornerstone of neonatal care for preterm respiratory distress syndrome (RDS). This review summarizes recent advances in surfactant therapy, focusing on surfactant composition and the clinical roles of surfactant proteins (SP-A, SP-B, SP-C, and SP-D), and highlights emerging strategies to optimize dosing and monitoring. We searched PubMed/MEDLINE, Embase, and the Cochrane Library for studies published between 2000 and 2025 using predefined keywords related to surfactant therapy, dosing, formulations, delivery techniques, monitoring, and outcomes. Evidence supports poractant alfa at an initial 200 mg/kg dose for improved early respiratory response and reduced need for re-treatment compared with lower dosing, and quantitative lung ultrasound is increasingly supported to guide surfactant timing and re-treatment decisions. Emerging innovations include SP-B/SP-C analog formulations and recombinant SP-D-based adjunct approaches, although several strategies remain investigational and require further validation.Conclusion: Key ongoing challenges include optimizing dosing and delivery efficiency, harmonizing monitoring and outcome definitions across studies, and improving cost-effectiveness. Overall, this review provides an updated critical perspective on surfactant therapy and future directions toward more individualized neonatal respiratory care.
Indexed as
Identifiers
41721093What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.